Cargando…
Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
The coronavirus disease 2019 (COVID-19) pandemic revolutionized the vaccine market and initiated the momentum for alternative routes of administration for vaccines. The intranasal route of immunization is one such possibility that appears to be the most promising since it has some significant advant...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200647/ https://www.ncbi.nlm.nih.gov/pubmed/35799869 http://dx.doi.org/10.7774/cevr.2022.11.2.184 |
_version_ | 1784728109305561088 |
---|---|
author | Meenakshi, Sarasa Kumar, V. Udaya Dhingra, Sameer Murti, Krishna |
author_facet | Meenakshi, Sarasa Kumar, V. Udaya Dhingra, Sameer Murti, Krishna |
author_sort | Meenakshi, Sarasa |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic revolutionized the vaccine market and initiated the momentum for alternative routes of administration for vaccines. The intranasal route of immunization is one such possibility that appears to be the most promising since it has some significant advantages, particularly in the prevention of respiratory infection. To analyze and summarize the role of nasal vaccines over conventional vaccines during COVID-19 and the need for the nasal vaccine as a booster shot. In this narrative review, the required data was retrieved using keywords “COVID-19,” “Intranasal,” “Immunity,” “Nasal spray,” and “Mucosal” in databases including PubMed, Scopus, Embase, Science Direct, and Web of Sciences. The results of the study showed that the nasal vaccines were both effective and protective according to the current researches approaching during the COVID-19 period and the preclinical and clinical phase trials prove the intranasal vaccination elicits more robust and cross-protective immunity than conventional vaccines. In this narrative review article, mechanisms across the nasal mucosa will be briefly presented and the current status of nasal vaccines during the COVID-19 pandemic is summarized, and advantages over traditional vaccines are provided. Furthermore, after exploring the primary benefits and kinetics of nasal vaccine, the potential for consideration of nasal vaccine as a booster dose is also discussed. |
format | Online Article Text |
id | pubmed-9200647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Vaccine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92006472022-07-06 Nasal vaccine as a booster shot: a viable solution to restrict pandemic? Meenakshi, Sarasa Kumar, V. Udaya Dhingra, Sameer Murti, Krishna Clin Exp Vaccine Res COVID-19 Special The coronavirus disease 2019 (COVID-19) pandemic revolutionized the vaccine market and initiated the momentum for alternative routes of administration for vaccines. The intranasal route of immunization is one such possibility that appears to be the most promising since it has some significant advantages, particularly in the prevention of respiratory infection. To analyze and summarize the role of nasal vaccines over conventional vaccines during COVID-19 and the need for the nasal vaccine as a booster shot. In this narrative review, the required data was retrieved using keywords “COVID-19,” “Intranasal,” “Immunity,” “Nasal spray,” and “Mucosal” in databases including PubMed, Scopus, Embase, Science Direct, and Web of Sciences. The results of the study showed that the nasal vaccines were both effective and protective according to the current researches approaching during the COVID-19 period and the preclinical and clinical phase trials prove the intranasal vaccination elicits more robust and cross-protective immunity than conventional vaccines. In this narrative review article, mechanisms across the nasal mucosa will be briefly presented and the current status of nasal vaccines during the COVID-19 pandemic is summarized, and advantages over traditional vaccines are provided. Furthermore, after exploring the primary benefits and kinetics of nasal vaccine, the potential for consideration of nasal vaccine as a booster dose is also discussed. The Korean Vaccine Society 2022-05 2022-05-31 /pmc/articles/PMC9200647/ /pubmed/35799869 http://dx.doi.org/10.7774/cevr.2022.11.2.184 Text en © Korean Vaccine Society. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | COVID-19 Special Meenakshi, Sarasa Kumar, V. Udaya Dhingra, Sameer Murti, Krishna Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title_full | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title_fullStr | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title_full_unstemmed | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title_short | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
title_sort | nasal vaccine as a booster shot: a viable solution to restrict pandemic? |
topic | COVID-19 Special |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200647/ https://www.ncbi.nlm.nih.gov/pubmed/35799869 http://dx.doi.org/10.7774/cevr.2022.11.2.184 |
work_keys_str_mv | AT meenakshisarasa nasalvaccineasaboostershotaviablesolutiontorestrictpandemic AT kumarvudaya nasalvaccineasaboostershotaviablesolutiontorestrictpandemic AT dhingrasameer nasalvaccineasaboostershotaviablesolutiontorestrictpandemic AT murtikrishna nasalvaccineasaboostershotaviablesolutiontorestrictpandemic |